AGP Executive Report
Last update: 4 hours agoFDA Oversight in Drug Safety: Absentia Labs’ AI Digital Liver Model for predicting drug-induced liver injury has been accepted into the FDA’s Drug Development Tool Qualification Program, aiming to cut costly drug failures. Biomanufacturing Deals: Vector Science & Therapeutics signed a landmark exclusive cGMP manufacturing agreement with LyoGenesis Plus for its peptide portfolio, boosting scale for clinical supply. Sustainable Pharma Chemistry: Cambrex and Snapdragon Chemistry won the ACS Green Chemistry Challenge Award for a greener synthetic route to a chiral drug core. Public Health Watch: US scientists are investigating a puzzling rise in cyclosporiasis linked to Cyclospora cayetanensis, using modern tracking to find sources in complex food supply chains. Food Allergy Rules: Codex adopted new guidance to make “may contain” allergen labels more consistent and science-based worldwide. Climate & Earth Risks: Studies flag stronger heat impacts and new geologic risk signals, including a previously unknown fault in South Africa’s Karoo Basin. Tech & Society: A new behavioral-science “0–10 Rule” study reports big burnout drops, while researchers map AI methods for restoring degraded face video.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
